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Original Article
A randomized controlled trial in
non-responders from Newcastle upon
Tyne invited to return a self-sample for
Human Papillomavirus testing versus
repeat invitation for cervical screening
Louise Cadman1, Scott Wilkes2, Diana Mansour3, Janet Austin1,
Lesley Ashdown-Barr1, Rob Edwards1, Michelle Kleeman1 and
Anne Szarewski1
Abstract
Background: Non-attenders for cervical screening are at increased risk of cervical cancer. Studies offering self-sampling for
high-risk Human Papillomavirus (HrHPV) testing have shown greater uptake than sending another invitation for cytology.
Objectives: To explore whether uptake would increase in a less diverse, more stable population than the previous English
study, which demonstrated a lower response rate than other studies. The primary objective was whether non-attenders were
more likely to respond to a postal invitation, including kit, to collect a self-sample compared with a further invitation for
cytology screening. The secondary objective was whether women with an abnormal result would attend for follow-up.
Methods: 6000 non-attenders for screening in this pragmatic, randomized (1:1) controlled trial in Newcastle-upon-Tyne were
sent an HPV self-sample kit (intervention) or a further invitation for cytology screening (comparator).
Results: 411(13%) responded to the intervention, returning a self-sample (247(8%)) or attending for cytology (164(5%)),
compared with 183(6%) attending for cytology, relative risk 2.25 (95% CI 1.90–2.65) (comparator arm). Of those testing
hrHPV positive (32(13%)), 19(59%) subsequently attended cytology screening. Of those in the intervention group who attended
for cytology screening without returning an hrHPV self-sample (n¼ 164), 5% (n¼ 8) were referred for colposcopy - all attended.
In the comparator group eight of the nine referred for colposcopy attended.
Conclusion: Persistent non-responders to invitations for cervical screening are significantly more likely to respond to a postal
invitation to return a self-collected sample for HPV testing than a further invitation for cytology screening. However, just over
half followed up on this positive HPV result.
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Introduction
Women who do not attend for regular cervical screening
are at increased risk of developing cervical cancer com-
pared with regular attendees.1 It has been estimated that
the cervical screening programme in England and Wales
has prevented up to 5000 deaths per year with three to ﬁve
yearly routine cytology screening.2 Attendance rates in the
United Kingdom (UK) have consistently declined in
recent years.3 In 2012–2013 78.3% were screened at least
once in the last ﬁve years, below the National Health
Service Cervical Screening Programme’s (NHSCSP)
target of 80%.3–6
Inequalities in the uptake of cancer screening have been
well documented, with poor uptake associated with ethnic
minority populations and social deprivation.7,8 Barriers to
attendance cited by women include fear or embarrass-
ment, pain, the gender of the sample taker, inconvenient
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appointment times, and diﬃculty arranging child-care or
time oﬀ work.6,9,10,11 Self-collected sampling may over-
come many of these barriers.
Clinician-collected samples for high-risk Human
Papillomavirus (hrHPV) testing have been shown to
oﬀer better protection against cervical cancer than cytol-
ogy alone.12–14 This procedure is being explored as the
primary test for screening programmes, with the
Netherlands the ﬁrst national programme due to adopt
it.15 It also has potential as a test carried out on cervico-
vaginal samples collected by women themselves, which has
been shown to have similar sensitivity and speciﬁcity to
clinician samples, although not with all hrHPV testing
platforms.16–19 In addition, self-collected sampling, using
devices such as swabs, brushes, tampons, or lavage, is
broadly acceptable to women.19–23
In the era of HPV prophylactic vaccination screening
programmes are likely to change. Participants in the
school-based vaccination programme in the UK are due
to be invited for screening as early as 2015. UK trials of
HPV testing as primary screening are currently underway.
The plan in the Netherlands is for HPV primary screening
with clinician samples, and to oﬀer self-sampling to non-
responders.15 This study should add useful information
for changing screening strategies.
In a number of studies of self-collected sampling to
increase screening in non-responders, the strategy appears
more eﬀective than sending another invitation for cytol-
ogy.17,24–31 Five studies have reported response rates to
self-sampling, ranging from 20 to 39%. However a sixth
study, carried out in a district of London with a highly
mobile population, of whom 65% were not from a white
British ethnic background, showed a lower response rate
of only 10.2%.29,32
The rationale for undertaking the present study in
Newcastle upon Tyne was to explore whether targeting
non-responders from a less diverse and more stable popu-
lation would improve uptake. Newcastle upon Tyne has a
population where 18% are not white British in contrast to
65% in the London study.32
Methods
Design
This trial was a pragmatic, randomized controlled trial of
6000 women randomized 1:1 to an intervention group or a
comparator group. The report of this clinical trial con-
forms to the CONSORT statement.33
Participants
Participants were selected from women in the Newcastle
upon Tyne region (a mixed urban/rural location typical of
the UK) who had failed to attend for cervical cytology.
These women were at point 4 on the North East Primary
Care Services Agency (NEPCSA) cervical screening
invitation letter schedule (Figure 1), and had received a
minimum of two invitations to attend for cervical screen-
ing. They were not all on three to ﬁve yearly recall, as
some were due for early cytology repeat. They were iden-
tiﬁed on 3 September 2012 via the Exeter National Health
Applications and Infrastructures Services System
(NHAISs) at NHS England, Durham, Darlington and
Tees and working on behalf of Cumbria and
Northumberland, Tyne and Wear Area Team
(formerly NEPCSA). NHAIS holds the screening infor-
mation of all women registered nationally with a
General Practitioner (GP). Routinely, women due for
screening are invited by the regional screening team. The
GP will be informed of women due for screening, and will
also be made aware of non-responders. They may, as a
point of good practice, contact the women, but the process
is primarily managed on a regional level.
Intervention and Comparator Groups
The intervention group received, by post, a Dacron swab
self-collection kit, specimen tube with specimen transport
medium (1ml), packaging material, trial information
including a self-sample collection instruction sheet, and a
consent form. They were asked to return their swab, con-
sent form, and contact details within three months, which
was deemed a reasonable response time. HrHPV samples
returned to the Centre for Cancer Prevention (CCP), with a
complete consent form and contact details, were tested
using Qiagen Hybrid CaptureII technology (Relative
Light Unit cutoﬀ >1 indicating hrHPV positive). The
hrHPV results were sent to the women by post and
although all women were advised that they should still
attend for screening, this was emphasized in the hrHPV
positive group. All women who did not respond, either to
the invitation or advice to follow up an hrHPV positive
result with cytology, were returned to the appropriate
point on the screening invitation letter schedule (Figure 1).
The comparator group received a further standard cer-
vical cytology invitation letter by post from the NHS
England screening team. They received their results in
the usual way, by letter from the screening oﬃce.
All women were advised that they should still attend for
routine cytology screening, and were returned to the
appropriate point on the screening invitation letter sched-
ule (Figure 1) if they failed to do so. All who had abnor-
mal cytology were managed routinely in accordance with
the NHSCSP.
Objectives
The primary objective was to ascertain whether non-atten-
ders were more likely to respond to a postal invitation to
collect a self-sample for hrHPV testing by returning the
test or attending for cytology screening, compared with a
further invitation for routine cytology screening. The sec-
ondary objective was to ascertain whether women with
abnormal results would attend for follow-up cytology or
colposcopy, if necessary.
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Outcomes
The primary outcome was the proportion of women
responding to the intervention by returning a self-sample
or attending for cytology screening, compared with the
number of women sent a further standard invitation for
cytology who attended within three months.
Secondary outcomes were compliance to follow up, and
included response to a positive hrHPV result by attending
for cytology within three months, and attending for
colposcopy in response to abnormal cytology within
four months.
Initial screening invite 
letter
Screening test due
+ 4-6 weeks
First reminder sent
+18 weeks
  
Fi t d d
+12 weeks
rs  non-respon er car  
sent to GP
+12 weeks
Second non-responder 
card sent to GP*
Returned to routine 3 or 5 
yearly screening
Point 
1
Point 
2
Good practice for GP to 
contact woman
Point 
4
Point 
3
GP should exception 
report
Figure 1. North of England Commissioning Cervical screening invitation letter schedule.
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Sample size
The sample size of 3000 women in each of the two arms
(intervention and comparator) is powered to detect a
moderate improvement in initial response, and a substan-
tial improvement in the proportions who attend colpos-
copy (after a positive screening test). Samples sizes were
based on 5% type I error and assumptions made based on
the results of the previous UK study.19 The primary out-
come was the proportion providing a screening sample,
assumed to be 7.5% in the comparator arm and 10.0%
in the intervention arm (based on response rates in the
previous English study).19 Allowing for 10% loss through
not reaching the person with the invitation (for example
no longer living at that address) and using a two-sided
chi-squared test statistic, 2984 women in each arm were
required to obtain 90% power. With 3000 patients in each
arm and assuming 0.4% of those sent a reminder letter
compared with 1.0% of those sent a self-sampling kit
would attend for colposcopy (as a result of the test
result), this would give 79.6% power to detect a diﬀerence
(two-sided).19
Randomization and blinding
As the trial aimed to evaluate an intervention in a popu-
lation of non-responders, Zelen’s design was adopted.34
By randomizing participants prior to consent, the poten-
tial response bias in the comparator group would be
avoided. The local screening team identiﬁed the number
of non-responders in a snapshot of all women at Point 4
on the NEPCSA cervical screening invitation letter sched-
ule on 3 September 2012 (Figure 1). A randomized list of
participant numbers (PNO) was produced at CCP using
an in-house computer application and balanced in blocks
of four without stratiﬁcation. PNOs were allocated to the
intervention group of 3000 (N) and comparator group of
3000 (C). The list of PNOs was emailed to the Newcastle
upon Tyne team in a Microsoft Excel format and inserted
into the list of women at Point 4, randomly allocating a
PNO to the trial cohort of 6000 women. The names,
addresses, and PNOs were securely emailed to the mailing
company contracted to NHS North of Tyne, the Mailing
House Group Limited, where the intervention packs and
comparator group letters were prepared and dispatched.
This ensured that the study team was blinded to the allo-
cation, and that those who did not consent to participate
in the study remained anonymous. Researchers had access
to all data of consented participants.
Statistical methods
The proportions of women responding to the intervention
(primary outcome) were calculated in the form of percent-
age of responders in each arm. The relative risks (RR)
were also calculated, with 95% conﬁdence intervals (CI).
Secondary outcomes were similarly measured as a propor-
tion of those responding in that category. Additional
analyses of the inﬂuence of covariates were carried out
using multivariate logistic regression.
Ethical Approval
This trial received ethical approval on 1 August 2012 from
NHS Health Research Authority, NRES Committee
North East – Sunderland (Reference 12/NE/0242).
Results
Recruitment and participant flow
All 6000 women were sent a self-sample collection pack or
invitation to attend for screening on 10 September 2012.
The ﬁnal date for either attendance for cytology screening
or self-collected sample return was 10 December 2012.
The cohort responses are shown in Figure 2. The last col-
poscopy was performed on 21 January 2013, when the last
person attending cytology underwent colposcopy within
the prescribed timeframe.
Baseline data
The median age of the total cohort was 40 (interquartile
range (IQR) 31–49); for the intervention group responders
was 41 (IQR 32–48) and for non-responders 39 (IQR
30–49), comparator group responders 41 (IQR 32–49)
and non-responders 39 (IQR 31–50) (Table 1). Of the
total cohort, 46% were in the most deprived national
quintile, and a further 19% in the second most deprived.
In 3789 women with a previous recorded cytology result,
the mean number of months from the last test was 92.9
(standard deviation 57.77, range 0.10–416.48 months);
2211 women had no record of previous cytology (Table 2).
This was a pragmatic trial with the total cohort of 6000
women included in the primary outcome analysis. There
were 438 (7%) letters and packs returned to sender, 226
from the comparator group and 212 from the intervention
group. The reasons for return included movement out of
the area (153 women), death, other reasons, or reasons not
given. There were no reported adverse events in the inter-
vention group.
Outcomes and estimations
The primary outcome showed 411 (13%) women in the
intervention arm responded to the intervention by return-
ing an hrHPV self-sample (247 (8%)) or attending for
cytology (164 (5%)) (Figure 2). This compares with
183 (6%) in the comparator arm responding to a further
invitation for cervical screening (RR 2.25 (95%CI 1.90 to
2.65). Women in the intervention arm were two times
more likely to respond, and this remained when adjusting
for age, deprivation status, or time since their last cytology
(RR 2.24 (CI 1.90–2.64). When response rates were
restricted to those whose invitations were not returned
to the sender, the rates increase in both groups, with 9%
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8737 non-responders to 
cytology screening
Intervention group (I) – Comparator group (C)Not included group (X)
Randomised I:C:X
1:1:0.9
   
sent HPV self-sample 
collection kit
n = 3000
HPV self-sample 
returned*
No 
response*
2589
Attended for 
cytology*
   
– sent further  cytology 
invitation
n = 3000
No 
response*
2817
Attended for 
cytology*
   
n = 2737
n =  247 (8%) 
Excluded n=1 
(not testable)
HPV positive
n =  32 (13%)
HPV negative
n = 214 (87%)
n =  
(86%) n = 164 (5%)
n =  
(94%) n = 183 (6%)
No 
response 
to HPV 
result**
n = 13
(41%)
Attended for 
cytology 
after HPV 
result**
n = 19 (59%)
Non-
attender
for 
cytology
**
n = 192 
(90%)
Attended 
for 
cytology 
after HPV 
result**
n = 22 
(10%)
Cytology 
borderline/
mild & 
HPV +ve,
Cytology 
negative, 
unsatisfactory, 
borderline/mil
Cytology 
borderline/
mild & 
HPV +ve,
Cytology 
negative, 
unsatisfactory, 
borderline/mild
Cytology 
borderline/
mild & 
HPV +ve,
Cytology 
negative, 
unsatisfactory, 
borderline/mild
Cytology 
borderline/
mild & 
HPV +ve,
Cytology 
negative, 
unsatisfactory, 
borderline/mild , 
or worse
n =  2
(11%)
Attended for Non-attender for
d & HPV -ve
n =  17 (89%)
  
or worse
n = 0 (0%)
Attended for 
colposcopy
Non-
attender for
 
& HPV -ve
n = 22 (100%)
  
or worse
n =  8
(5%)
Non-
attender for
Attended for 
colposcopy
 
& HPV -ve
n = 156 (95%)
  
or worse
n =  9 (5%)
Non-
attender for
Attended for 
colposcopy
 
& HPV -ve
n = 174 (95%)
***
n = 2 
(100%)
 
colposcopy
***
n = 0 (0%)
 
***
n =  0
 
colposcopy colposcopy 
***
n =  0 
 
colposcopy 
***
n =  0 (0%)
 
***
n =  8 
(100%)
 
colposcopy 
***
n =  1 (11%)
 
***
n =  8 (89%)
* within 3 months of correspondence being despatched
** within 3 months of result letter being sent
*** within 4 months of the date the cytology sample was taken
Figure 2. Participant Flow Chart.
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(212 of 2788) returning a self-sample and 6% attending
for cytology in the intervention group, and 7% (173 of
2744) attending for cytology in the comparator group. If
the 28 women who attended for cytology within two
months prior to the study invitation (whose attendance
would not yet have been recorded on the Exeter system)
were removed from the analysis, the ﬁgures remain
similar: 14% response in the intervention group and 6%
in the comparator (RR 2.00(1.69–2.34))
The hrHPV positivity rate in the intervention arm was
13% (n¼ 32) and of these, 41% (n¼ 13) did not attend for
cytology screening. Of the 59% (n¼ 19) who did attend,
the cytology results in 11% (n¼ 2) required further follow
up with colposcopy in accordance with NHSCSP guide-
lines, and both attended (Table 3). Both women had
results of severe dyskaryosis (Table 4); one was was
aged 27, with no previous cytology, the other, aged 47,
had had three previous negative smears, the most recent in
1996. Both had CINIII conﬁrmed on Large Loop
Excision of the Transformation Zone (LLETZ).
Of the women in the intervention group who responded
by attending for cytology screening, rather than returning
an hrHPV self-sample (n¼ 164), 5% (n¼ 8) were referred
to colposcopy in accordance with NHSCSP guidelines,
and all eight women (100%) attended. There were two
referrals with high grade cytology – severe dyskaryosis
and severe dyskaryosis with possible invasion. Both were
found to have CINIII after LLETZ. In the comparator
group, nine women required referral for colposcopy fol-
lowing abnormal cytology results. Three had cytology
results of borderline dyskaryosis with hrHPV triage test
positive. A further three had mild dyskaryosis and hrHPV
positive, and two had severe dyskaryosis. The ﬁnal woman
had possible glandular neoplasia. Of these nine women,
Table 1. Demographics by allocation group and response.
Intervention group Comparator group
Non-responders
(% row)
Responders
(% row)
Non-responders
(% row)
Responders
(% row) RR (95% CI)
Age category
25–29 558 (90) 63 (10) 555 (95) 27 (5) 2.19 (1.41 to 3.38)
30–34 451 (86) 73 (10) 480 (93) 36 (7) 2.00 (1.37 to 2.92)
35–39 303 (84) 59 (16) 374 (95) 20 (5) 3.21 (1.97 to 5.22)
40–44 331 (83) 69 (17) 352 (92) 29 (8) 2.27 (1.50 to 3.42)
45–49 312 (84) 59 (16) 333 (92) 28 (8) 2.05 (1.34 to 3.14)
50–54 334 (88) 47 (12) 359 (93) 27 (7) 1.76 (1.12 to 2.77)
55–59 196 (85) 34 (15) 255 (96) 11 (4) 3.58 (1.85 to 6.89)
60–65 104 (94) 7 (6) 109 (96) 5 (4) 1.44 (0.47 to 4.40)
Total 2589 (86) 411 (14) 2817 (94) 183 (6) 2.25 (1.90 to 2.65)
Time from last cytology to date of invitation
No previous cytology 1032 (92) 86 (8) 1060 (97) 33 (3) 2.55 (1.72 to 3.77)
>10 years 425 (90) 48 (10) 481 (98) 11 (2) 4.54 (2.39 to 8.63)
5–10 years 671 (84) 126 (16) 718 (93) 54 (7) 2.26 (1.67 to 3.06)
3–5 years 417 (75) 138 (25) 503 (87) 76 (13) 1.89 (1.47 to 2.44)
0–3 years 44 (77) 13 (23) 55 (86) 9 (14) 1.62 (0.75 to 3.51)
Deprivation status (national quintiles)
Most deprived 1177 (86) 198 (14) 1299 (95) 73 (5) 2.71 (2.09 to 3.50)
2nd most deprived 492 (88) 70 (13) 547 (95) 27 (5) 2.65 (1.73 to 4.07)
Middle quintile 279 (87) 42 (13) 295 (91) 29 (9) 1.46 (0.94 to 2.29)
2nd least deprived 347 (85) 59 (15) 361 (93) 28 (7) 2.02 (1.32 to 3.10)
Least deprived 294 (88) 42 (13) 315 (92) 26 (8) 1.64 (1.03 to 2.61)
Table 2. Time between last cytology and date of invitation by age
category.
Years between last cytology and date of invitation
Age group
(years)
No previous
cytology
0–3
years
3–5
years
5–10
year
>10
years Total
25 to 29 1059 18 74 49 3 1203
30 to 34 498 30 221 227 64 1040
35 to 39 210 19 201 222 104 756
40 to 44 139 15 217 266 144 781
45 to 49 105 15 225 216 171 732
50 to 54 98 12 189 268 200 767
55 to 59 69 10 4 238 175 496
60 to 65 33 2 3 83 104 225
Total 2211 121 1134 1569 965 6000
6 Journal of Medical Screening 0(0)
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89% (n¼ 8) attended for colposcopy. Two required
LLETZ for CINII and CINIII. The one woman who
did not attend colposcopy within three months did
attend within six months, following a severely dyskaryotic
smear, with CINIII conﬁrmed on LLETZ.
Influence of covariates
The response rate in the intervention arm was similar
across all deprivation quintiles (13–15%). This was not
the same in the comparator group, where the two most
deprived quintiles showed a 5% response rate, whereas the
three least deprived showed 7–9%. Women in the inter-
vention group were more likely to be responders than
those in the comparator group in all age groups except
those aged 60 to 65 (RR 1.44 (95% CI 0.47–4.40)).
This could be a reﬂection of the small numbers in this
age group (Table 1). The time since last cytology
and response to intervention was statistically signiﬁcant
for both intervention and comparator groups, with
those who had no previous cytology being less likely
to respond (p< 0.01). Women in the intervention group
were more likely to respond, except in those who had
attended for cytology within the last ﬁve years (Table 1).
Of those never screened, or not screened within the last
ten years, 6% were responders to the interventions
(Table 1).
Multivariate analyses showed increasing response with
increasing age and the probability of responding increased
with decreasing deprivation (p¼ 0.004), however, the rela-
tive risk for the interaction was 1.01 (1.00–1.02). There
was no signiﬁcant interaction (not shown) between age
Table 3. Cytology results.
Cytology result
Intervention group responders
(% of column*)
(cytology either as a response
to the invitation to return a
self-sample or after receiving
hrHPV result)
Comparator group
responders
(% of column*)
(cytology as a response
to a routine screening
invitation letter) Total
Inadequate 3 (2) 4 (2) 8
Negative 188 (92) 167 (91) 392
Borderline & hrHPV negative 4 (2) 2 (1) 7
Mild & hrHPV negative 0 (0) 1 (1) 1
Borderline & hrHPV positive 5 (2) 3 (2) 8
Mild & hrHPV positive 1 (1) 3 (2) 4
Moderate 0 (0) 0 (0) 0
Severe 3 (2) 2 (1) 7
Severe ? Invasive 1 (1) 0 (0) 1
? Glandular neoplasia 0 (0) 1 (1) 1
Total 205 183 429
*Figures rounded up and may be equal to more than 100%.
Table 4. Histology results in women referred to colposcopy who attended within six months.
Worst histology
Cytology result No histology Borderline/basal atypia HPV only CIN1 CIN2 CIN3 Total
Intervention group responders
Borderline & hrHPV positive 2 2 0 1 0 0 5
Mild & hrHPV positive 0 0 0 1 0 0 1
Severe 0 0 0 0 0 3 3
Severe ? Invasive 0 0 0 0 0 1 1
Comparator group responders
Borderline & hrHPV positive 0 0 1 1 1 0 3
Mild & hrHPV positive 0 0 0 3 0 0 3
Severe 0 0 0 0 0 1 1
? Glandular neoplasia 1 0 0 0 0 0 1
Total 3 2 1 6 1 5 18
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and time since last cytology (p¼ 0.088), nor deprivation
and time since last cytology (p¼ 0.109).
Discussion
This pragmatic randomized controlled trial in non-
responders to invitations to attend for cervical screening
has shown a response rate to the intervention of posting a
self-sample collection kit for HPV testing of 13%, com-
pared with 6% of the comparator group, who responded
to a further invitation to attend for cytology. Of this 13%,
8% returned a self-collected sample, and 5% chose to
attend for cytology screening. Randomization to interven-
tion or comparator group ensured balanced distribution
of potentially inﬂuential factors. It is diﬃcult to mitigate
against the intervention group responding to a diﬀerent
type of correspondence, as it is to quantify whether being
encouraged to still attend for cervical screening as part of
the NHSCSP discouraged some women from returning a
self-sample. This response rate, although higher than the
previous UK study, is still lower than in other countries.29
This may be a reﬂection of the diﬀerent deﬁnitions of non-
responders in the cohorts, or the interventions in some
studies immediately preceding the self-collection kit,
such as pre-invitation letters.26,31,35,36 The ﬁndings of
this pragmatically designed trial can be generalized to
the English NHSCSP, however, the outcomes can also
be generalized to a wider population, when considered
as part of the pool of evidence of self-collected cervico-
vaginal sampling in non-responders.
Of the women testing hrHPV positive, only 59%
attended for cytology, which raises concerns about the
CIN which remains undetected and untreated. This
response rate was lower than for the previous English
study, possibly because the London study oﬀered
women cytology in a research clinic, whereas this study
was more pragmatic and women were advised to arrange
and attend for screening under their own auspices. The
hrHPV positivity rate in this group was higher than that
found in previous studies at 13%, compared with 8.3% in
studies of a comparable age group in the UK using the
same hrHPV test.29,37 This could be explained by this
study cohort’s lower median age: 41(IQR 32–48) versus
47.5 (40.5–54.5) in the previous English study. However,
less that 1% of women returning a self-sampling test
required colposcopic examination and, although numbers
were too small to be of great signiﬁcance, high grade CIN
was detected and treated in 100% of cases. In those
undergoing cytology screening alone, 4.6% required col-
poscopy, and 25% of these women had high grade disease
diagnosed and treated at colposcopy. The attendance rates
for colposcopy were the same in both groups. This diﬀered
from the previous study in London, but again could be
explained by oﬀering women in the intervention group
colposcopy at the same time as cytology in the research
clinic. It could be hypothesized that the colposcopy
attendance in this pragmatic study better replicates the
non-study situation.
Deprivation is associated with non-attendance for cer-
vical screening, and in Newcastle as a whole, it would be
expected that 40% of the population would be in the two
most deprived national quintiles.38 In this study cohort of
non-responders, however, this ﬁgure reaches 65%, which
supports the association between deprivation and non-
attendance for cervical screening. Deprivation does not
appear to be a barrier to returning a self-sample, as
68% of responders in the self-sample group lived in the
two most deprived quintiles, compared with 57% in both
arms who attended for cytology screening ﬁrst. The acces-
sibility of self-sampling, without the need to take time oﬀ
work, travel to the clinic, or arrange childcare, may be of
beneﬁt to those from lower resource settings.
This trial supports the increasing evidence that self-
sampling for hrHPV testing is eﬀective for women not
currently being reached by organized screening pro-
grammes.16,17 However, there are cost implications in
sending out self-collection kits to all women considered
non-responders. Twelve test kits were sent for every one
returned, and approximately 40% of the expenditure in
the intervention arm was the cost of producing and send-
ing kits.39 This compared with 15% of the overall cost in
the comparator arm of sending out repeat invitations.
The estimated cost per high grade CIN detected was,
however, similar in both the comparator and intervention
arms (ratio 1:1.09). This was not the case when those in
the intervention group who attended for cytology screen-
ing, rather than return a self-sample, and those testing
HPV negative were excluded (ratio 1:1.36). A full
economic analysis is required before such a strategy can
be adopted.
HrHPV testing is being considered as the primary cer-
vical screening method for the UK, where trials are cur-
rently underway, and in countries where cervical
screening programmes are not yet established.12 There
is also interest in self-sampling for HPV testing as a
method of primary screening in countries where
resources and access to healthcare and healthcare profes-
sionals are limited.40,41 Although this is a reasonable
option for non-responders to invitations for screening,
it would be of value to explore more cost-eﬀective
approaches to target non-responders. When considered
as primary screening, self-collection for HPV testing
tends to have a lower sensitivity and speciﬁcity compared
with clinician samples. A recent meta-analysis suggested
that the pooled sensitivity for self-collected samples in
primary screening for the detection of CIN2 or worse
was 76% (95% CI 69 to 92) and speciﬁcity 86% (95%
CI 83 to 89) versus 91% (95% CI 87 to 94) sensitivity
and 88% (95% CI 85 to 91) speciﬁcity for clinician sam-
ples.16 Although HPV testing from self-collected samples
in its current form is not the preferred test to a clinician
sample, there is evidence to suggest that selecting the
correct test (Polymerase Chain Reaction based) or adapt-
ing the testing methodology for self-sampling (such as
raising the cut-oﬀ point for positivity) could improve
the sensitivity and speciﬁcity.16,42
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